During the last session, Travere Therapeutics Inc (NASDAQ:TVTX)’s traded shares were 3.48 million, with the beta value of the company hitting 0.72. At the end of the trading day, the stock’s price was $17.11, reflecting an intraday loss of -2.73% or -$0.48. The 52-week high for the TVTX share is $17.77, that puts it down -3.86 from that peak though still a striking 70.08% gain since the share price plummeted to a 52-week low of $5.12. The company’s market capitalization is $1.31B, and the average intraday trading volume over the past 10 days was 3.02 million shares, and the average trade volume was 1.66 million shares over the past three months.

Travere Therapeutics Inc (TVTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.47. TVTX has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.67.

Travere Therapeutics Inc (NASDAQ:TVTX) trade information

Travere Therapeutics Inc (TVTX) registered a -2.73% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.73% in intraday trading to $17.11, hitting a weekly high. The stock’s 5-day price performance is 25.35%, and it has moved by 39.79% in 30 days. Based on these gigs, the overall price performance for the year is 122.50%. The short interest in Travere Therapeutics Inc (NASDAQ:TVTX) is 6.96 million shares and it means that shorts have 2.9 day(s) to cover.

The consensus price target of analysts on Wall Street is $21.5, which implies an increase of 20.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $30 respectively. As a result, TVTX is trading at a discount of -75.34% off the target high and 29.87% off the low.

Travere Therapeutics Inc (TVTX) estimates and forecasts

Statistics show that Travere Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Travere Therapeutics Inc (TVTX) shares have gone up 155.75% during the last six months, with a year-to-date growth rate more than the industry average at 22.09% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -134.00% this quarter and then jump 51.70% in the quarter after that. In the rating firms’ projections, revenue will increase 55.10% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 60.87M as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to 67.58M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 37.09M and 45.06M respectively. In this case, analysts expect current quarter sales to grow by 64.10% and then jump by 50.00% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.34%. While earnings are projected to return -131.36% in 2024.

TVTX Dividends

Travere Therapeutics Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 7.5 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 9.6774% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $61.65 million.